Isocitrate Dehydrogenase (IDH) inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018

Isocitrate Dehydrogenase (IDH) inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018

  • Pages: 59
  • Geography: Global
  • Delivery Timeline: 24 Hours
  • Publication: Jul, 2018
  • SKU: DISR0019
  • Single User License
    (20% Off)
    $3,000.00
  • Site License
    (30% Off)
    $6,000.00
  • Global License
    (40% Off)
    $9,000.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

"Isocitrate Dehydrogenase (IDH) inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018", report provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. The report provides the detailed analysis of 8+ products along with 5+ companies involved. Agios Pharmaceuticals and Novartis are developing therapeutic drugs in the higher phase and Agios has been granted Orphan and Fast-track Designation both from FDA. 
Products covered by Phase

• Phase III, Phase II and Phase I 

• Pre-clinical and Discovery
Overview of pipeline development activities for Isocitrate Dehydrogenase (IDH) inhibitors
Pipeline analysis of 8+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.
Therapeutic segmentation of products for Isocitrate Dehydrogenase (IDH) inhibitors
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism of action. 
Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. 
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases. 
Scope 

• The report provides competitive pipeline landscape of Isocitrate Dehydrogenase (IDH) inhibitors 

• The report provides the marketed drugs information including its sales, development activities and details of patent expiry

• The report provides the insight of current and future market for Isocitrate Dehydrogenase (IDH) inhibitors 

• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

• Coverage of the Isocitrate Dehydrogenase (IDH) inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

• The report reviews key players involved in the therapeutics development for Isocitrate Dehydrogenase (IDH) inhibitors and also provide company profiling

• Pipeline products coverage based on various stages of development ranging from late stage till discovery stage

• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to Buy

• Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

• Establish a comprehensive understanding of the current pipeline scenario across Isocitrate Dehydrogenase (IDH) inhibitors to formulate effective R&D strategies

• Assess challenges and opportunities that influence Isocitrate Dehydrogenase (IDH) inhibitors R&D

• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine

• Devise corrective measures for pipeline projects by understanding Isocitrate Dehydrogenase (IDH) inhibitors pipeline depth and focus of target therapeutics

• Developing strategic initiatives to support your drug development activities

• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Isocitrate Dehydrogenase (IDH) inhibitors to enhance and expand business potential and scope 

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

• Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs

• Gaining a full picture of the Competitive Landscape for Evidence based Decisions

 

Executive Summary
IDH Targets
Overview
Competitive Landscape
Marketed Product
Idhifa: Celgene Corporation
Product Description
Research and Development
Pipeline Activity
Product Development Activities
Idhifa Sales
Pipeline Therapeutics
Comparative Analysis
Late Stage Products
Comparative Analysis
AG-120: Agios Pharmaceuticals
Product Description
Research and Development
Product Development Activities
AG-120 (Ivosidenib) Sales
(The list continues)
Mid-Stage Products
Comparative Analysis
Early Stage Products
Comparative Analysis
Pre-clinical and Discovery Stage Products
Comparative Analysis
Therapeutic Assessment
Institutional Product
Dormant Products
Comparative Analysis
Market Drivers and Barriers
Appendix

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Dormant Products

 

Figure 1: Mechanism of IDH Inhibitors
Figure 2: Idhifa Forecasted Sales
Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
Figure 4: Late Stage Products (Phase III)
Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products 
Figure 9: Assessment by Monotherapy Products 
Figure 10: Assessment by Route of Administration 
Figure 11: Assessment by Stage and Route of Administration 
Figure 12: Assessment by Molecule Type 
Figure 13: Assessment by Stage and Molecule Type 
Figure 14: Dormant Products 

 

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.